Food and Drugs Administration
Biological Response Modifiers Advisory Committee
October 10, 2002
Slides
Retroviral Insertional Mutagenesis and Cancer in Animal Models, Dr. Linda Wolff, PhD, NIH HTM Ppt
AML in Mice After Retroviral Cell Marking HTM Ppt
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dr. Stuart Orkin, MD and Dr. Amo Motulsky, MD HTM Ppt
Treatment of Patients With Persistent Immune Defects Despite Allogeneic Bone Marrow Transplantation HTM Ppt
Self-Inactivating LTRs and Chromatin Insulators, Philippe Leboulch, Genetix Pharmaceuticals, Inc. PDF